Bristol-Myers Squibb (Japan)

Recent papers from Bristol-Myers Squibb (Japan)

1. Efficacy and safety of lisocabtagene maraleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: 31-month follow-up of the phase 2 TRANSCEND FL studyInternational Journal of Clinical Oncology · 2026
2. Evolution of Real-World Treatment Patterns over Time in Patients with HER2-Negative Advanced Gastric Cancer: A Retrospective Database Cohort Study from JapanAdvances in Therapy · 2026
3. Cendakimab for Eosinophilic Gastritis and Duodenitis in Japanese Adults and Adolescents: Results From a Phase 3 Randomized Controlled TrialThe American Journal of Gastroenterology · 2026
4. P1.100. Impact of Immunotherapy Introduction on Real-World Treatment Patterns for Advanced Esophageal Cancer: A Retrospective Database Cohort Study From JapanDiseases of the Esophagus · 2026
5. Evaluation of gastrointestinal and hepatic immune-related adverse events associated with nivolumab plus ipilimumab for unresectable advanced/recurrent pleural mesothelioma in JapanScientific Reports · 2026
6. Safety and Efficacy of Deucravacitinib in Japanese Patients With Moderate to Severe Plaque Psoriasis: 5‐Year Analysis of the Phase 3 POETYK PSO ‐1, PSO ‐4, and Long‐Term Extension TrialsThe Journal of Dermatology · 2026
7. Efficacy and safety of ozanimod in Japanese patients with moderately to severely active ulcerative colitis naive to immunomodulators or advanced therapies: post hoc analysis of the phase 2/3 J-True North studyIntestinal Research · 2026
8. Characteristics and Future Perspectives of Available Electronic Health Record Databases in JapanDrugs - Real World Outcomes · 2026
9. Correction: An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT studyGastric Cancer · 2026
10. Delirium-related adverse events and malpractice claims in Japan: an exploratory comparative analysis of national adverse event data and closed claimsBMC Geriatrics · 2026
11. A39-10 Assessment of Pharmacokinetic Interactions between Admilparant (BMS-986278) and Nintedanib or PirfenidoneAmerican Journal of Respiratory and Critical Care Medicine · 2026
12. Nivolumab plus ipilimumab and cobimetinib in previously treated microsatellite-stable/DNA mismatch repair-proficient metastatic colorectal cancer: the phase II CheckMate 142 trialESMO Gastrointestinal Oncology · 2026
13. Quality of Life, Symptom Burden, and Associated Factors Among Patients With Lung Cancer in Sub-Saharan Africa: Cross-Sectional StudyJMIR Cancer · 2026
14. Pd-Catalyzed Buchwald-Hartwig Coupling of Imidazo[1,2-b]pyridazine with Aryl/Hetero Aryl Amines for the Synthesis of Functionalized PyridazinesSynthesis · 2026
15. Interpreting the statistical analysis results of a virtual control group in toxicity studies and potential applicability of an artificial synthetic control groupNAM journal. · 2026
16. A Minimum 3‐Year Follow‐Up of Nivolumab‐Plus‐Ipilimumab in Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma: A Final Analysis of the J‐ ENCORE StudyInternational Journal of Urology · 2026
17. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trialAnnals of Oncology · 2026
18. Abstract PS5-03-09: Trial in progress: A phase 2/3 trial of iza-bren (BMS986507/BL-B01D1), an EGFRxHER3 antibody-drug conjugate, vs standard-of-care chemotherapy in patients with previously untreated, locally advanced, recurrent inoperable, or metastatic triple negative breast cancer ineligible for anti-PD-(L)1 treatment (IZABRIGHT-Breast01)Clinical Cancer Research · 2026
19. EZClust: A Robust Machine Learning-Based Powder X-Ray Diffraction and Raman Cluster Analysis Model for Efficient High-Throughput Crystallization Polymorph ScreeningOrganic Process Research & Development · 2026
20. Interfacility variations in blood chemistry parameters and their implications for virtual control group constructionNAM journal. · 2025